PemPress - All Posts Archives | IPPF

COVID-19 Pandemic and Autoimmune Bullous Diseases

The results of our survey are published in the...

April 5, 2021Anna Lane

Statement Regarding Anti-Asian Racism and Healthcare Inequities

March 25, 2021One of the most important functions of...

March 25, 2021Patrick Dunn

NORD Statement about the American Rescue Plan

The National Organization for Rare Disorders (NORD) Rare Action...

March 19, 2021Anna Lane

The Urgent Needs of Pemphigus Patients: Elevating Awareness

The IPPF has published a white paper focusing on...

March 16, 2021Anna Lane

Information for Pemphigus and Pemphigoid Patients Related to COVID-19

Vaccination Information Related to Autoimmune Bullous Diseases The information...

March 10, 2021Patrick Dunn

Rare Disease Day and Rare Across America: 2021

We are rare, we are many, we are strong,...

February 19, 2021Anna Lane

Patient-initiated Dermatology Research Needs Pemphigus and Pemphigoid Participants

The International Alliance of Dermatology Patient Organizations (also known...

January 12, 2021Anna Lane

Janet Segall: Foundation of Hope

I'm in awe of the wonderful people who have...

November 24, 2020Anna Lane

David Baron: Diagnosis and Hope

Any time I’ve needed help, the IPPF has been...

November 6, 2020Anna Lane

Hannah Yale: Empowerment through Community

Empowerment through community: I have often felt powerless when...

October 30, 2020Patrick Dunn

Inspiring Hope: Ellen’s Story

Thanks to modern medicine, great physicians, and the IPPF,...

October 21, 2020Anna Lane

Inspiring Hope: Noel’s Story

The articles on the IPPF website became my daily...

October 16, 2020Anna Lane

The IPPF Welcomes a New Executive Director

“I am delighted to join the Foundation. It is...

September 22, 2020Marc Yale

Rituximab to be Included in Taiwan’s National Health Insurance (NHI) Program to Treat Pemphigus Vulgaris

Several new drugs used to treat different types of...

September 9, 2020Patrick Dunn

Cabaletta Bio Receives FDA Fast Track Designation for DSG3- CAART for the Treatment of Mucosal PV

The U.S. FDA has granted Fast Track Designation for...

May 7, 2020Patrick Dunn

Advocacy in Action

You may be aware of the IPPF’s advocacy efforts....

February 25, 2020Rebecca Strong

Cabaletta Bio Announces FDA Orphan Drug Designation for DSG3- CAART for the Treatment of Pemphigus Vulgaris

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the...

February 17, 2020Patrick Dunn

Positive Proof-of-Concept Data for Efgartigimod in Pemphigus Vulgaris

23 patients were evaluated for efficacy in an adaptive...

January 5, 2020Patrick Dunn

Phase III PEMPHIX Study Shows Genentech’s Rituxan (Rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris

Genentech, a member of the Roche Group, announced data...

October 15, 2019Patrick Dunn

Cabaletta Bio Receives IND Clearance from FDA to Initiate First Clinical Trial of DSG3-CAART in Patients with Mucosal Pemphigus Vulgaris

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the...

October 4, 2019Patrick Dunn

X

Chinese (Simplified)